SLC5A11: A drug target and biomarker for the treatment of sodium and myo-inositol-related disorders

Target Name: SLC5A11

NCBI ID: G115584

SLC5A11

SLC5A11: A drug target and biomarker for the treatment of sodium and myo-inositol-related disorders

Introduction

Sodium (Na+) and myo-inositol (Insulin-like growth factor 1, IGF-1) are essential nutrients for the survival and proper functioning of the human body. However, abnormal levels of these ions can lead to various disorders, including diabetes, hypertension, and obesity. The SLC5A11 gene, located on chromosome 11, has been identified as a key regulator of sodium and myo-inositol homeostasis. In this article, we will discuss the SLC5A11 gene, its function, and its potential as a drug target and biomarker for the treatment of sodium and myo-inositol-related disorders.

SLC5A11 gene function

The SLC5A11 gene encodes a protein known as sodium/myo-inositol transporter 2 (SLC5A11). This protein plays a crucial role in regulating the movement of sodium and myo-inositol ions into and out of cells. SLC5A11 is expressed in the brain, heart , and pancreas, and its function is essential for the normal development and function of these organs.

SLC5A11 gene disorders

SLC5A11 gene disorders are a result of mutations in the SLC5A11 gene. These mutations can alter the structure and function of the SLC5A11 protein, leading to the disruption of sodium and myo-inositol homeostasis. Some of the most common SLC5A11 gene disorders include:

1. SLC5A11 gene expression has a high incidence rate in children and is the main cause of deafness.

SLC5A11 gene disorders have been identified in a significant number of individuals, including those with hearing loss and those with a family history of hearing loss. This suggests that SLC5A11 gene mutations may play a role in the development of hearing loss in humans.

2. SLC5A11 gene is a potential drug target

The SLC5A11 gene has been identified as a potential drug target for the treatment of sodium and myo-inositol-related disorders. By modulating the function of SLC5A11, researchers may be able to develop new treatments for these disorders.

3. SLC5A11 gene is a potential biomarker

The SLC5A11 gene has also been identified as a potential biomarker for the diagnosis and monitoring of sodium and myo-inositol-related disorders. By analyzing the expression of SLC5A11 in body tissues and fluids, researchers may be able to develop new diagnostic tests for these disorders. and monitor the effectiveness of new treatments.

SLC5A11 gene therapy

Sodium and myo-inositol play a critical role in the regulation of various physiological processes in the body, including muscle and nerve function. SLC5A11 gene therapy aims to restore the function of SLC5A11 by introducing a normal or functional copy of the gene into cells. This approach may be a promising new treatment option for individuals with sodium and myo-inositol-related disorders.

Conclusion

In conclusion, the SLC5A11 gene has been identified as a key regulator of sodium and myo-inositol homeostasis. Its dysfunction has been associated with a number of disorders, including diabetes, hypertension, and obesity. As a result, the SLC5A11 gene has great potential as a drug target and biomarker for the treatment of these disorders. Further research is needed to understand the full function of SLC5A11 and to develop new treatments based on this gene.

Protein Name: Solute Carrier Family 5 Member 11

Functions: Involved in the sodium-dependent cotransport of myo-inositol (MI) with a Na(+):MI stoichiometry of 2:1 (PubMed:15172003, PubMed:19032932). Exclusively responsible for apical MI transport and absorption in intestine (By similarity). Can also transport D-chiro-inositol (DCI) but not L-fucose (PubMed:15172003, PubMed:19032932). Exhibits stereospecific cotransport of both D-glucose and D-xylose (By similarity). May induce apoptosis through the TNF-alpha, PDCD1 pathway (PubMed:15172003, PubMed:18069935). May play a role in the regulation of MI concentration in serum, involving reabsorption in at least the proximal tubule of the kidney (By similarity)

The "SLC5A11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC5A11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets